Erleada Archives -

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up

Bayer triples sales forecast for prostate cancer drug Nubeqa

https://pharmaphorum.com/news/bayer-triples-sales-forecast-for-prostate-cancer-drug-nubeqa/

Bayer’s Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track

Trial closes gap between Bayer’s Nubeqa and rivals in prostate cancer

https://pharmaphorum.com/news/trial-narrows-gap-between-bayers-nubeqa-and-rivals-in-prostate-cancer/

NICE has reversed its position on Johnson & Johnson’s oral prostate cancer therapy Erleada in patients with hormone-relapsed

NICE changes its mind on J&J’s Erleada in prostate cancer

https://pharmaphorum.com/news/nice-changes-its-mind-on-jjs-erleada-in-prostate-cancer/

Pfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a

Xtandi catches up with Erleada in castration-sensitive prostate cancer

https://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/

Erleada